{"filing":{"accession_number":"0001193125-26-385881","cik":"0001422143","ticker":"KURA","company_name":"Kura Oncology, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"d496500d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/d496500d8k.htm"},"events":[{"id":32171,"run_id":29553,"accession_number":"0001193125-26-385881","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Kura Oncology formed a wholly owned subsidiary (Caspian Therapeutics) and contributed material intellectual property and assets (including compound KO-7246 and menin inhibitor patents) in exchange for equity ownership, while retaining ~49.2% of Caspian post-financing. This represents a significant strategic restructuring and spin-out of a business line focused on cardiometabolic diseases, coupled with a $50 million Series A financing in which the parent invested $4.3 million. While this involves subsidiary financing and asset contribution, it is primarily a strategic operational and organizational event rather than a traditional M\u0026A transaction, debt issuance, or equity dilution of the parent company itself.","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35282,"accession_number":"0001193125-26-385881","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Kura Oncology formed a wholly owned subsidiary (Caspian Therapeutics) and contributed material intellectual property and assets (including compound KO-7246 and menin inhibitor patents) in exchange for equity ownership, while retaining ~49.2% of Caspian post-financing. This represents a significant strategic restructuring and spin-out of a business line focused on cardiometabolic diseases, coupled with a $50 million Series A financing in which the parent invested $4.3 million. While this involves subsidiary financing and asset contribution, it is primarily a strategic operational and organizational event rather than a traditional M\u0026A transaction, debt issuance, or equity dilution of the parent company itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:05:43.156763+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35282,"accession_number":"0001193125-26-385881","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Kura Oncology formed a wholly owned subsidiary (Caspian Therapeutics) and contributed material intellectual property and assets (including compound KO-7246 and menin inhibitor patents) in exchange for equity ownership, while retaining ~49.2% of Caspian post-financing. This represents a significant strategic restructuring and spin-out of a business line focused on cardiometabolic diseases, coupled with a $50 million Series A financing in which the parent invested $4.3 million. While this involves subsidiary financing and asset contribution, it is primarily a strategic operational and organizational event rather than a traditional M\u0026A transaction, debt issuance, or equity dilution of the parent company itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:05:43.156763+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-09-09"}]}